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FraOBJECTIVES The aim of this study was to determine baseline characteristics and clinical outcomes of patients with
pre-existing atrial ﬁbrillation (AF) and of patients who presented with new-onset AF after transcatheter aortic valve
implantation (TAVI).
BACKGROUND Little is known regarding the impact of AF after TAVI.
METHODS The FRANCE-2 registry included all patients undergoing TAVI (N ¼ 3,933) in France in 2010 and 2011.
New-onset AF was deﬁned as the occurrence of AF post-procedure in a patient with no documented history of AF.
RESULTS AF was documented before TAVI in 25.8% of patients. New-onset AF was observed in 174 patients after TAVI
among patients without a history of pre-existing AF (6.0%). At 1 year, the rates of all-cause death (26.5 vs. 16.6%,
respectively; p < 0.001) and cardiovascular death (11.5 vs. 7.8%, respectively; p < 0.001) were signiﬁcantly higher in
patients with pre-existing AF compared with those without AF. Rehospitalization for worsening heart failure and New
York Heart Association functional class was also higher in patients with pre-existing AF versus those without, resulting in
a higher rate of combined efﬁcacy endpoint in this group (p < 0.001). A history of stroke, surgical (nontransfemoral)
approach, cardiological, and hemorrhagic procedure-related events were all independently related to the occurrence of
new-onset post-procedural AF. New-onset AF in patients without pre-existing AF was associated with a higher rate of
combined safety endpoint at 30 days (p < 0.001) and a higher rate of both all-cause death and combined efﬁcacy
endpoint at 1 year (p ¼ 0.003 and p ¼ 0.02, respectively).
CONCLUSIONS Pre-existing and new-onset AF are both associated with higher mortality and morbidity after TAVI.
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1347AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
AR = aortic regurgitation
AS = aortic stenosis
ECG = electrocardiogram
EuroSCORE = European
System for Cardiac Operative
Risk Evaluation
LVEF = left ventricular
ejection fraction
NYHA = New York Heart
Association
SAVR = surgical aortic valve
replacement
STS = Society of Thoracic
SurgeonsA trial ﬁbrillation (AF) is the most common car-diac arrhythmia, and its prevalence increasesprogressively with age to reach >10% in pa-
tients aged 80 years of age and older (1,2). In elderly
patients with severe degenerative aortic stenosis
(AS), coexisting AF is even more frequent (25% to
35%) (3–6) due to chronic left ventricular and left
atrial pressure overload (7), with important implica-
tions for prognosis. In fact, among patients with
AS undergoing conventional surgical aortic valve
replacement (SAVR), pre-existing AF is an indepen-
dent predictor of perioperative and long-term
adverse events, including mortality, congestive heart
failure, and stroke (5,6,8). Moreover, the occurrence
of new-onset AF after cardiac surgery is associated
with increased early and late morbidity and mortality
(9–11).SEE PAGE 1356
TAVI = transcatheter aortic
valve implantation
VARC2 = Valve Academic
Research Consortium
classiﬁcation 2
Transcatheter aortic valve implantation (TAVI) has
emerged as a viable alternative to SAVR for patients
with severe symptomatic AS who are considered to be
ineligible or at very high risk for conventional SAVR
(12,13). Little is known regarding the impact of
pre-existing or new-onset AF after TAVI, with few
speciﬁc studies that had small sample sizes and pre-
sented conﬂicting results (14–16).
The aims of the present study were therefore 1) to
compare baseline characteristics and long-term clin-
ical outcomes after TAVI between patients with and
without pre-existing AF and 2) to analyze baseline
characteristics, predictive factors, and prognostic
value of new-onset AF after TAVI among patients who
had no history of AF before the procedure, using data
from FRANCE-2, the French national TAVI registry.
METHODS
The FRANCE-2 registry is a multicenter, prospective
registry including 33 centers in France and 1 in
Monaco. Details of the registry have previously been
described (3). Brieﬂy, patients included in the registry
were symptomatic adults with severe AS who were
not candidates for SAVR because of coexisting illness.zzDepartment of Cardiovascular Surgery, CHU Lille, Lille, France; xxUniversity
and Vascular Surgery, Rennes University Hospital, Rennes, France; {{Jacque
Pasteur, Toulouse, France. The FRANCE 2 registry was supported by Edwa
proctor for Edwards Lifesciences. Dr. Eltchaninoff is a proctor for and receiv
is a consultant for Abbott, Boehringer Ingelheim, and Valtech and r
Dr. Leprince is a proctor for Medtronic and receives speaker fees from
Medtronic. All other authors have reported that they have no relationship
Manuscript received January 19, 2015; revised manuscript received April 16,Severe AS was deﬁned as an aortic valve area
of <0.8 cm2, a mean aortic valve gradient
of $40 mm Hg, or a peak aortic jet velocity
of $4.0 m/s. All patients had New York Heart
Association (NYHA) functional class II, III, or
IV symptoms. All patients who underwent
TAVI based on these criteria in France and
Monaco from January 2010 to December 2011
were prospectively included in the registry,
without exclusion criteria. Patients provided
written informed consent before undergoing
the procedure. The registry was approved by
the Institutional Review Board of the French
Ministry of Health.
STUDY POPULATIONS. In total, 3,933 pa-
tients undergoing TAVI were enrolled in the
FRANCE-2 registry from January 2010 to
December 2011. Information regarding a his-
tory of AF was available for 3,875 (98.5%),
and these patients comprise the study popu-
lation for the comparison of pre-existing
versus no pre-existing AF. After TAVI, 2,622 of the
2,873 patients (91.3%) without a history of AF before
the procedure were still alive at the ﬁrst in-hospital
follow-up. These patients constitute the study sam-
ple for the second analysis regarding the impact of
new-onset AF after TAVI (Online Figure 1). In-hospital
follow-up was performed 6  4 days (minimum of
2 days) after the procedure and included a systematic
review of all electrocardiographic events after TAVI
identiﬁed by serial review of post-procedural 12-lead
electrocardiograms (ECGs). AF was deﬁned as the
presence of an irregular rhythm with ﬁbrillatory
waves and no P waves on the ECG. Because atrial
ﬂutter is another supaventricular rhythm that may
coexist or precede AF, we assigned patients with
atrial ﬂutter to the new-onset AF group (17).
Risk factors for surgery were evaluated prospec-
tively using the Society of Thoracic Surgeons (STS)
(18) and the logistic European System for Cardiac
Operative Risk Evaluation (EuroSCORE) (19). Two
TAVI devices, commercially available at the onset of
the registry, were used: the self-expandable Med-
tronic CoreValve (Medtronic, Inc., Minneapolis,Lyon 1, Lyon, France; kkDivision of Thoracic, Cardiac
s Cartier Institute, Massy, France; and the ##Clinique
rds Lifesciences and Medtronic. Dr. Meneveau is a
es lecture fees from Edwards Lifesciences. Dr. Iung
eceives speaker fees from Edwards Lifesciences.
Edwards Lifesciences. Dr. Teiger is a proctor for
s relevant to the contents of this paper to disclose.
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1348Minnesota) and the balloon-expandable Edwards
SAPIEN valve (Edwards Lifesciences, Irvine, Califor-
nia). AF was managed according to current guidelines
(17). After the procedure, in patients with no indica-
tion for long-term anticoagulation, acetylsalicylic
acid was prescribed indeﬁnitely in combination with
clopidogrel for 6 months. In patients with an indica-
tion for oral anticoagulation, a vitamin K antagonist
was prescribed in combination with either acetylsa-
licylic acid or clopidogrel, at the discretion of the
investigator.
CLINICAL FOLLOW-UP. Clinical follow-up was
obtained for all patients at a median of 310 days
(Q1-Q3 ¼ 190 to 400). Mortality and all adverse
events during the procedure, at 30 days, and at 1 year
were assessed according to the Valve Academic
Research Consortium classiﬁcation 2 (VARC2) (20)
and adjudicated by an independent clinical events
committee. The combined safety endpoint was
deﬁned at 30 days and included all-cause mortality,
stroke (disabling and nondisabling), life-threatening
bleeding, acute kidney injury stage 2 or 3 (including
renal replacement therapy), coronary artery obstruc-
tion requiring intervention, major vascular complica-
tion, or valve-related dysfunction requiring repeat
intervention (i.e., TAVI, SAVR, balloon aortic valvulo-
plasty). The combined efﬁcacy endpoint was evalu-
ated at 1 year and deﬁned as all-causemortality, stroke
(disabling and nondisabling), need for hospitalization
for valve-related symptoms or worsening congestive
heart failure, NYHA functional class III or IV, valve-
related dysfunction (mean aortic valve gradient
>20 mm Hg, effective oriﬁce area <0.9 to 1.1 cm2, and/
or Doppler velocity index <0.35 m/s, and/or moderate
or severe prosthetic valve regurgitation.
Procedure-related events were deﬁned as those
occurring during or as a direct result within 24 h
after TAVI and were classiﬁed as cardiological
(myocardial infarction, ventricular or supraventricu-
lar arrhythmia, complete atrioventricular block, need
for pacemaker implantation, heart failure, tampo-
nade), vascular (hemorrhage, arterial thrombosis/
dissection/rupture, aortic dissection), hemorrhagic
(life-threatening or not, tamponade), neurological
(minor or major stroke), valvular (valve migration,
aortic annulus rupture, aortic valve insufﬁciency),
and conversion to surgery (20).
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD when normally distributed
or median  interquartile range if not normally
distributed and compared using the Student t test or
Wilcoxon rank sum test as appropriate. Categorical
variables are described as number (percentage) andcompared using the chi-square or Fisher exact test.
We compared 30-day and 1-year VARC2–deﬁned
clinical outcomes: 1) between patients with pre-
existing AF versus those without; and 2) between
patients with persistent sinus rhythm versus patients
with new-onset AF after TAVI. Outcome analyses
were adjusted for baseline and procedural character-
istics using multivariate logistic regression analysis
or a Cox model (after veriﬁcation of the underlying
assumption of proportionality of hazard) that
included variables with a p value <0.10 by univariate
analysis. Results are reported as the odds ratio or
hazard ratio with associated 95% conﬁdence interval,
as appropriate, and p value. The Kaplan-Meier
method was used to create survival curves at 1 year.
Interactions between pre-existing AF and sex, age,
logistic EuroSCORE, STS score, chronic obstructive
pulmonary disease, chronic kidney disease, periph-
eral artery disease, low left ventricular ejection frac-
tion (LVEF) (#35%), pulmonary hypertension, and
type of device implanted were tested by the Breslow-
Day test. Independent predictors of the occurrence
of new-onset AF after TAVI were analyzed by multi-
variate logistic regression, including all baseline
and procedural characteristics with a p value <0.10
by univariate analysis. All p values are 2-sided. A
p value <0.05 was considered statistically signiﬁcant.
Statistical analyses were performed with SAS version
9.3 (SAS Institute Inc., Cary, North Carolina).
RESULTS
PRE-EXISTING VERSUS NON–PRE-EXISTING AF. Basel ine
and procedura l character i s t i cs in the overa l l
populat ion . Overall, AF was documented before
TAVI (pre-existing AF) in 1,002 patients (25.8%).
Tables 1 and 2 display the baseline and procedural
characteristics of patients with and without pre-
existing AF. Patients in the pre-existing AF group
were more frequently male, were older and presented
with higher rates of several major comorbidities (i.e.,
previous stroke, pulmonary hypertension, permanent
pacemaker) and worse NYHA functional class. Device
success and procedure-related events were similar
between patients with and without pre-existing AF,
except for the rate of VARC2–deﬁned cardiological
events, which was lower in the pre-existing AF group.
The rate of signiﬁcant post-procedural aortic regur-
gitation (AR) (grade 2 or higher) did not differ sig-
niﬁcantly between groups. Echocardiographic data at
baseline are shown in Table 3. We observed a lower
LVEF, a higher pulmonary pressure, and a higher
rate of signiﬁcant mitral regurgitation in the group of
patients with pre-existing AF.
TABLE 1 Baseline Clinical Characteristics in the Overall Population (N ¼ 3,875) and in the Population of Patients Without a History of
Atrial Fibrillation (n ¼ 2,622)
Pre-Existing AF
p Value
New-Onset AF
p Value
No
(n ¼ 2,873)
Yes
(n ¼ 1,002)
No
(n ¼ 2,448)
Yes
(n ¼ 174 )
Age, yrs 82.6  7.4 83.5  6.0 0.001 82.4  7.5 83.7  6.7 0.03
Women 1,475 (51.3) 439 (43.8) <0.001 1,257 (51.3) 80 (46.0) 0.18
BMI, kg/m2 25.9  5.1 26.1  4.7 0.55 26.0  5.7 25.9  5.4 0.74
STS score 13.6  11.4 15.4  11.6 <0.001 13.3  11.3 14.1  12.3 0.41
Logistic EuroSCORE 20.8  13.6 24.5  15.1 <0.001 20.5  13.4 22.1  12.5 0.11
NYHA functional class III or IV 2,108 (73.3) 803 (80.1) <0.001 1,793 (73.2) 118 (67.8) 0.13
Clinical history
Diabetes 710 (24.7) 276 (27.5) 0.08 600 (24.6) 44 (25.3) 0.85
Hypertension 2,011 (70.0) 656 (65.5) 0.004 1,710 (70.3) 129 (74.1) 0.30
CAD 1,394 (48.5) 450 (44.9) 0.03 1,178 (48.4) 90 (51.7) 0.43
Previous CABG 515 (17.9) 171 (17.1) 0.51 442 (18.1) 30 (17.2) 0.83
PAD 793 (27.6) 283 (28.2) 0.69 660 (27.0) 59 (34.1) 0.052
Previous stroke 263 (9.1) 119 (11.9) 0.01 210 (8.6) 24 (13.8) 0.02
CKD 236 (8.2) 96 (9.6) 0.18 183 (7.5) 19 (11.0) 0.10
COPD 650 (22.6) 225 (22.4) 0.91 545 (22.3) 43 (24.9) 0.45
Permanent pacemaker 340 (11.8) 202 (20.1) <0.001 290 (11.8) 21 (12.1) 0.90
Left bundle-branch block 335 (11.6) 122 (12.1) 0.56 285 (11.7) 20 (11.5) 1.0
LVEF <30% 197 (6.8) 84 (8.4) 0.10 175 (7.1) 5 (2.9) 0.01
Pulmonary hypertension 639 (22.2) 354 (35.3) <0.001 529 (21.7) 47 (27.2) 0.10
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; BMI ¼ body mass index; CABG ¼ coronary artery bypass graft surgery; CAD ¼ coronary artery disease; CKD ¼ chronic kidney disease; COPD ¼ chronic
obstructive pulmonary disease; EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association; PAD ¼ peripheral artery disease; STS ¼ Society of Thoracic Surgeons.
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1349Cl in i ca l outcomes in the overa l l populat ion .
VARC2–deﬁned clinical outcomes in the overall pop-
ulation through 30 days and 1 year are summarized in
Table 4. During the ﬁrst 30 days, we observed similar
rates of death and overall procedure-related compli-
cations, including the combined safety endpoint,
between those with and without pre-existing AF. At
1 year, all-cause death and cardiovascular death were
signiﬁcantly higher among patients with pre-existing
AF (p < 0.001 and p < 0.001, respectively). Figure 1A
illustrates the survival probability curves after TAVI
for patients with and without pre-existing AF. The
rate of rehospitalization for worsening heart failure or
valve dysfunction was higher, and NYHA functional
class was worse in case of pre-existing AF, resulting in
a higher rate of the combined efﬁcacy endpoint in this
group (p < 0.001). The rates of stroke and major
bleeding at 1 year were similar between groups.
Cox analysis showed that pre-existing AF was the
second most powerful predictor of mortality after
TAVI, after post-procedural AR (Figure 2A). By strat-
iﬁed analysis, the increased 1-year mortality risk
among patients with pre-existing AF was consistent
across major subgroups, including sex, age, logistic
EuroSCORE, STS score, chronic obstructive pulmo-
nary disease, chronic kidney disease, peripheralartery disease, low LVEF (#35%), pulmonary hyper-
tension, and type of device implanted (Figure 3).
On echocardiographic follow-up, we observed that
LVEF remained lower, whereas pulmonary pressure
and the rate of signiﬁcant mitral regurgitation were
signiﬁcantly higher in the pre-existing AF group
(Table 3).
NEW-ONSET AF. Baseline and procedural characteristics
in the population without a history of AF. Among the
2,873 patients without a history of AF, post-
procedural ECG review could not be performed due
to in-hospital death of 251 patients. A comparison of
the baseline characteristics of these 251 patients and
of those in whom post-procedural ECG review was
performed and is presented in Online Table 1. No
signiﬁcant difference was observed between the 2
populations.
New-onset AF was observed in 174 patients (6.0%)
after TAVI among patients without a history of
pre-existing AF. Patients in whom new-onset AF
developed were older and presented with a higher
rate of previous stroke compared with those who
remained in sinus rhythm (Table 1). Regarding
procedural characteristics, device success and post-
procedural AR were similar between groups.
TABLE 2 Procedural Characteristics, Procedural Success, and Related Events in the Overall Population (N ¼ 3,875) and in the Population of
Patients Without a History of Atrial Fibrillation (n ¼ 2,622)
Pre-Existing AF
p Value
New-Onset AF
p Value
No
(N ¼ 2,873 )
Yes
(n ¼ 1,002)
No
(n ¼ 2,448 )
Yes
(n ¼ 174 )
Procedural characteristics
General anesthesia 1,993 (69.4) 673 (67.1) 0.20 779 (31.8) 35 (20.2) 0.001
Access route
Transapical 539 (18.7) 151 (15.1) 0.008 421 (17.2) 56 (32.2) <0.001
Transfemoral 2,068 (72.0) 759 (75.7) 0.02 1,817 (74.2) 99 (56.9) <0.001
Subclavian 154 (5.3) 68 (6.8) 0.09 123 (5.0) 7 (4.0) 0.71
Transaortic 95 (3.3) 20 (2.0) 0.04 73 (3.0) 12 (6.9) 0.005
Type of valve 0.007 0.17
Edwards SAPIEN valve
(Edwards Lifesciences, Irvine, California)
1,943 (67.6) 633 (63.2) 1,657 (67.7) 127 (72.9)
Medtronic CoreValve
(Medtronic Inc., Minneapolis, Minnesota)
930 (32.4) 369 (36.8) 791 (32.3) 47 (27.1)
Procedural success 2,702 (94.0) 947 (94.5) 0.64 2,383 (97.3) 169 (97.1) 0.80
Procedure-related event
Conversion 21 (0.73) 8 (0.8) 0.83 13 (0.5) 0 (0) 1.0
Cardiological 425 (14.8) 118 (11.8) 0.01 323 (13.2) 36 (20.7) 0.008
Hemorrhagic 287 (10.0) 85 (8.5) 0.17 219 (8.9) 27 (15.5) 0.006
Vascular 176 (6.1) 65 (6.5) 0.70 149 (6.1) 9 (5.2) 0.74
Neurological 58 (2.0) 18 (1.8) 0.79 44 (1.8) 2 (1.1) 0.76
Valvular 53 (1.8) 25 (2.5) 0.23 32 (1.3) 3 (1.7) 0.50
Post-procedural paravalvular AR >2 337 (11.7) 140 (16.9) 0.08 306 (12.5) 23 (13.2) 0.81
Values are n (%).
AF ¼ atrial ﬁbrillation; AR ¼ aortic regurgitation.
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1350Conversely, the rate of use of an approach other
than the transfemoral approach (i.e., surgical trans-
apical and transaortic approaches) was signiﬁcantly
higher in the new-onset patient group, as was the
rate of VARC2–deﬁned cardiological events and
hemorrhagic procedure–related events (Table 2).
A history of stroke, surgical nontransfemoral
approach, cardiological and hemorrhagic procedure–
related events were all found to be independently
related to the occurrence of new-onset post-TAVI
AF (Table 5).
Cl in i ca l outcomes in the populat ion without a
h is tory of AF . Table 4 displays the VARC2–deﬁned
outcomes after TAVI in the population without a
history of AF. The duration of hospital stay was
signiﬁcantly longer in patients with new-onset AF
after TAVI (12.5  11.3 vs. 9.9  9.5, respectively;
p < 0.001). New-onset AF was associated with a
higher rate of the combined safety endpoint at
30 days (p < 0.001). At 1 year, both all-cause death
and the combined efﬁcacy endpoint were signiﬁ-
cantly higher in the new-onset AF group (p ¼ 0.003
and p ¼ 0.02, respectively), whereas the rates of
stroke and major bleeding were similar. The survival
probability curves for patients with no history of AF
and in whom new-onset AF developed after TAVI aredisplayed in Figure 1B. Multivariate analysis showed
that new-onset AF after TAVI was one of the main
predictors of mortality, along with renal failure and
AR (Figure 2B) in patients with no history of AF.
Finally, echocardiographic follow-up did not reveal
any differences between groups (Online Table 2).
DISCUSSION
This large prospective study investigating concomi-
tant AF in patients with severe AS undergoing TAVI
showed that both pre-existing and new-onset AF
were associated with higher mortality and morbidity
at 1 year. The higher rate of death observed in pre-
existing AF patients seems to be linked to heart
failure, whereas the poorer outcome in patients in
whom new-onset AF developed after TAVI could be
related to the procedure.
Since the PARTNER (Placement of Aortic Trans-
catheter Valve) trials (12,13), several prognostic factors
for TAVI have been identiﬁed, such as low LVEF (21),
pulmonary hypertension (22), and post-procedural
AR grade 2 or higher (23). A recent analysis from
the PARTNER I trial showed that body mass index,
coagulopathy, chronic kidney disease, liver disease,
cognitive status, STS score, and periprocedural
TABLE 3 Echocardiographic Evolution After TAVI in the Overall
Population (N ¼ 3,875)
Pre-Existing AF
p Value
No
(N ¼ 2,873 )
Yes
(n ¼ 1,002)
LVEF, %
Baseline value 53.9  14.2 51.4  14.0 <0.001
First FU 57.4  12.1 54.8  12.2 <0.001
Last FU 58.0  12.1 55.8  12.0 <0.001
Systolic PAP, mm Hg
Baseline value 43.7  13.9 49.1  13.7 <0.001
First FU 39.1  13.1 45.9  13.3 <0.001
Last FU 38.7  12.8 45.1  15.1 <0.001
Mitral regurgitation
3/4 or 4/4
Baseline 48 (1.7) 27 (2.7) 0.04
First FU 19 (0.7) 22 (2.2) 0.003
Last FU 19 (0.7) 18 (1.8) 0.006
Values are mean  SD or n (%). First FU performed at a median of 35 days
(Q1-Q3 ¼ 27 to 42); last FU performed at a median of 310 days (Q1-Q3 ¼ 190
to 400). Comparisons of ﬁrst FU and last FU were adjusted for baseline value.
FU¼ follow-up; PAP¼ pulmonary artery pressure; other abbreviations as in Table 1.
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1351complications were related to mortality between 30
days and 1 year after TAVI (24). In the present study,
we observed that AF, whether pre-existing or new
onset among patients without a history of AF beforeTABLE 4 VARC-Deﬁned Outcomes at 30 Days and 12 Months in the O
With No History of Atrial Fibrillation (n ¼ 2,622)
Pre-Existing AF
No Yes OR/HR (95%
Length of hospital stay, days 10.1  10.6 10.7  8.4 1.34 (0.95
At 30 days
All-cause death 246 (8.56) 113 (11.3) 1.15 (0.78
Cardiovascular death 160 (5.6) 65 (6.5) 1.10 (0.81–
All stroke 97 (3.4) 27 (2.7) 0.81 (0.52
Acute kidney injury 39 (1.4) 20 (2.0) 1.18 (0.60
Myocardial infarction 40 (1.4) 8 (0.8) 1.73 (0.80
Major bleeding 283 (9.8) 82 (8.2) 1.12 (0.86
Major vascular complication 112 (3.9) 45 (1.1) 1.14 (0.80
Valve-related dysfunction 522 (18.2) 167 (16.7) 0.91 (0.75–
Safety endpoint 1,045 (36.4) 364 (36.3) 1.006 (0.86
At 1 yr
All-cause death 477 (16.6) 266 (26.5) 1.72 (1.42–
Cardiovascular death 225 (7.8) 115 (11.5) 1.96 (1.44–
All stroke 119 (4.1) 34 (3.4) 0.87 (0.59
Major bleeding 320 (11.1) 104 (10.4) 0.85 (0.64
Rehosp. 246 (8.6) 161 (10.1) 2.02 (1.63–
NYHA functional class III or IV 255 (8.9) 165 (16.5) 1.85 (1.52–
Valve-related dysfunction 113 (3.9) 45 (4.5) 1.14 (0.79
Efﬁcacy endpoint 968 (33.7) 470 (46.9) 1.55 (1.36–
Values are n (%).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; OR ¼ odds ratio; Rehosp. ¼ rehospitali
as in Table 1.TAVI, represents a key predictor of late mortality after
TAVI, with an impact of the same magnitude as that of
AR and chronic kidney disease.
Pre-ex is t ing AF. Regarding pre-existing AF, we
observed some differences in the clinical character-
istics between patients with and without a history of
AF, resulting in a signiﬁcantly higher preoperative
logistic EuroSCORE and STS risk scores in the pre-
existing AF group. However, all baseline characteris-
tics were included in the multivariate analysis, and,
thus, the results were observed independently of
these factors.
Our results are in line with and strengthen pre-
liminary reports from 2 previous registries (25,26)
and from 2 speciﬁc reports (15,16). However,
these previous studies included limited sample sizes
(fewer than 400 patients in each study), and found a
1.44- to 4.11-fold increased risk of all-cause mortality
at 1 year. In light of these results, the inclusion of pre-
existing AF in future risk scores speciﬁcally dedicated
to selection of patients for either TAVI or SAVR
should be considered.
The higher rate of death observed among
pre-existing AF patients undergoing TAVI is in
accordance with outcomes after SAVR in which pre-
existing AF is associated with a 1.5-fold increase inverall Population (N ¼ 3,875) and in the Population of Patients
New-Onset AF
CI) p Value No Yes OR/HR (95% CI) p Value
–1.87) 0.08 9.9  9.5 12.5  11.3 1.77 (1.34–2.33) <0.001
–1.71) 0.46 78 (3.2) 11 (6.3) 1.87 (0.85–4.1) 0.11
1.49) 0.52 42 (1.7) 6 (3.4) 1.80 (0.59–5.51) 0.30
–1.25) 0.35 73 (2.9) 9 (5.1) 1.75 (0.86–3.59) 0.12
–2.31) 0.62 25 (1.0) 4 (2.3) 1.91 (0.64–5.70) 0.24
–3.73) 0.15 33 (1.3) 1 (0.6) 3.11 (0.41–23.1) 0.26
–1.46) 0.36 217 (8.9) 24 (13.8) 0.70 (0.44–1.12) 0.14
–1.64) 0.45 91 (9) 9 (5.1) 1.72 (0.84–3.51) 0.13
1.10) 0.36 431 (17.6) 32 (18.4) 1.70 (0.72–1.60) 0.72
–1.48) 0.77 778 (31.2) 72 (41.4) 1.45 (1.06–1.99) <0.001
2.1) <0.001 271 (11.1) 36 (20.7) 1.79 (1.21–2.65) 0.003
2.67) <0.001 97 (4.0) 11 (6.3) 1.74 (0.86–3.51) 0.11
–1.30) 0.87 89 (3.6) 9 (5.1) 1.05 (0.49–2.19) 0.90
–1.10) 0.10 396 (10.7) 28 (16.1) 0.84 (0.57–1.23) 0.37
2.52) <0.001 233 (9.1) 136 (16.4) 1.22 (0.62–2.40) 0.55
2.26) <0.001 191 (7.8) 18 (10.3) 1.28 (0.79–2.08) 0.31
–1.63) 0.46 103 (4.2) 8 (4.6) 1.11 (0.53–2.27) 0.78
1.77) <0.001 713 (29.1) 73 (41.9) 1.44 (1.1–1.87) 0.02
zation for worsening heart failure or valve-related dysfunction; other abbreviations
FIGURE 2 Predicto
Correlates of pre-exi
LVEF ¼ left ventricu
FIGURE 1 1-Year Follow-Up Survival Curves
Kaplan-Meier curves of 1-year survival probability in patients with and without pre-existing atrial ﬁbrillation (AF) (A) and in patients with and
without new-onset AF among the population without a history of AF (B).
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1352the risk of death in an overall population (6) and an
8-fold increase in risk in case of concomitant reduced
LVEF (5).
The higher rate of death at 1 year observed in the
pre-existing AF group was not related to procedure-
related adverse events at 30 days, but rather was
associated with heart failure symptoms, including a
higher rate of rehospitalization for worsening heart
failure and a poorer NYHA functional class. Further-
more, echocardiographic analysis at baseline and
during follow-up showed worse cardiac function in
the pre-existing AF group. Therefore, the worsers of 1-Year Mortality After TAVI
sting (A) and new-onset atrial ﬁbrillation (AF) (B) by multivariate Cox mode
lar ejection fraction.outcome after TAVI observed in patients with pre-
existing AF could be the expression of advanced
heart disease. In this context, structural remodeling
and myocardial ﬁbrosis are important synergistic
contributors to the AF substrate, which increase mor-
tality by accelerating the process of ventricular
and atrial senescence (27). Moreover, the loss of
atrioventricular synchrony, leading to impaired ven-
tricular ﬁlling, reduced cardiac output, and increased
afterload, are hemodynamic factors known to
adversely affect clinical outcomes in heart failure pa-
tients (28).ls. AR ¼ aortic regurgitation; NYHA ¼ New York Heart Association;
FIGURE 3 Stratiﬁed Analysis of All-Cause Mortality in the Overall Population
Stratiﬁed analysis for all-cause mortality among subgroups in patients with and without pre-existing atrial ﬁbrillation (AF). CI ¼ conﬁdence
interval; COPD ¼ chronic obstructive pulmonary disease; CKD ¼ chronic kidney disease; LVEF ¼ left ventricular ejection fraction;
PAD ¼ pulmonary arterial disease.
TABLE 5 Independent Predictors of the Occurrence of New-Onset Atrial
Fibrillation After TAVI
Univariate Model Multivariate model
HR (95% CI) p Value HR (95% CI) p Value
Previous stroke 1.69 (1.07–2.66) 0.02 1.66 (1.05–2.63) 0.03
PAD 1.39 (1.008–1.93) 0.04 —
LVEF <30% 0.38 (0.15–0.95) 0.03 —
Nontransfemoral access 2.18 (1.59–2.98) <0.001 2.04 (1.47–2.81) 0.001
Cardiological procedure–related event 1.71 (1.16–2.52) 0.006 1.59 (1.08–2.36) 0.01
Hemorrhagic procedure–related event 1.86 (1.21–2.88) 0.004 1.56 (1.004–2.45) 0.04
TAVI ¼ transcatheter aortic valve implantation; other abbreviations as in Tables 1 and 4.
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1353New-onset AF. In this study, we observed that
new-onset AF developed in 6% of patients after TAVI
and was directly related to the procedure itself,
including the use of a surgical nontransfemoral
approach and the occurrence of hemorrhagic and
cardiological procedural adverse events. Compared
with SAVR, the prevalence of new-onset AF in
patients undergoing TAVI was lower (29), but patho-
physiological mechanisms could share some common
features, especially in the case of a transapical
approach. First, it is well known from thoracic surgery
that thoracotomy is associated with new-onset AF
due to the ventilatory restriction and the hyper-
adrenergic status generated by postoperative pain
(30). Second, bleeding events (31) and myocardial
injury such as left ventricular repair or cardiological
complications (32) were previously shown to be
strongly related to the occurrence of new-onset AF
after open-heart surgery.
New-onset AF was associated in our study with
poorer outcomes after TAVI compared with patients
without a history of AF, a longer hospital stay, a
higher rate of combined safety procedure-relatedendpoint at 30 days, and a higher rate of both all-
cause mortality and the combined efﬁcacy endpoint
at 1 year. To the best of our knowledge, this is the ﬁrst
study to report such results in a large registry popu-
lation. Two previous studies that both included pre-
existing and new-onset AF found that the mortality
rate was not signiﬁcantly different compared with
patients without new-onset AF (15,16). In addition,
Amat-Santos et al. (14) showed, in a dedicated study,
PERSPECTIVES
WHAT IS KNOWN? In patients with AS undergoing
conventional surgical aortic valve replacement,
pre-existing AF is an independent predictor of peri-
operative and long-term adverse events. Similarly,
occurrence of new-onset AF after cardiac surgery is
associated with increased early and late morbidity
and mortality.
WHAT IS NEW?We show that both pre-existing and
new-onset AF represent major predictors of 1-year
mortality after TAVI, without any difference in the
rate of stroke and bleeding. Our data suggest that the
worse outcome observed in patients with pre-existing
AF may be the expression of advanced heart disease.
The occurrence of new-onset AF after TAVI and the
excess mortality that it engenders could be related to
the thoracic surgical approach and periprocedural
complications.
WHAT IS NEXT? The inclusion of pre-existing AF in
future risk scores dedicated to selection of patients
for either TAVI or SAVR should be considered, and
speciﬁc post-procedural management could be
envisaged for patients in whom new-onset AF de-
velops after TAVI.
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1354in 138 high-risk patients undergoing TAVI a higher
rate of cerebrovascular events, but not death during
30-day follow-up in patients with new-onset AF
(n ¼ 44) (14).
Stroke and major b leed ing . Population-based
studies indicate a 5-fold increase in the risk of stroke
and systemic embolism in individuals with AF com-
pared with those with sinus rhythm (33,34), as well
as an increased risk of bleeding related to anticoag-
ulant therapy (35). In the present study, contrary to
preliminary reports (14,16), we did not observe any
difference in the rate of stroke or major bleeding
between patients with and without pre-existing or
new-onset AF as a potential explanation for differ-
ences in mortality and morbidity.
STRENGTH AND LIMITATIONS. This study has several
strong points. First, this is the only large-scale TAVI
registry to investigate this issue, and we included all
consecutive patients treated in a deﬁned geographic
territory over a given period, thus limiting the risk
of selection bias as much as possible. It is also by far
the largest multicenter registry available, including
nearly 4 times more patients and analyzing nearly
twice as many events than the largest studies avail-
able to date, and allowing extensive multivariate
adjustment (21).
Conversely, this study also has some limitations
that deserve to be emphasized. First, some echocar-
diographic variables were not recorded at baseline and
during follow-up, including left atrial size, myocardial
mass, and other speciﬁc hemodynamic data. Indeed,
an atrial size of $27 mm/m2 was identiﬁed as the
cutoff point for the detection of new-onset AF after
TAVI within 30 days in a previous study (14). Next, the
FRANCE-2 registry was not powered to analyze
outcomes according to the different type of AF
(i.e., paroxysmal, persistent or permanent). Previous
studies have shown that patients undergoing TAVI
with AF had an increased risk of death irrespective of
the type of AF (15). Finally, despite careful and com-
plete assessment of patient data, it is always possible
that some episodes of asymptomatic paroxysmal AF
may have gone undetected.
CONCLUSIONS
Both pre-existing and new-onset AF represent major
predictors of 1-year mortality after TAVI. We did not
observe any difference in the rate of stroke and
bleeding between patients with and without AF as a
potential explanation for differences in mortality.
The worse outcome observed in patients with pre-
existing AF seems to be the expression of advancedheart disease, as suggested by echocardiographic
data and the higher rate of heart failure adverse
events observed in this group. The occurrence of
new-onset AF after TAVI and the excess mortality
that it engenders could be related to the thoracic
surgical approach and periprocedural complica-
tions, especially VARC2–deﬁned cardiological and
hemorrhagic events. The inclusion of pre-existing AF
in future risk scores dedicated to the selection of
patients for either TAVI or SAVR should be consid-
ered, and speciﬁc post-procedural management could
be envisaged for patients in whom new-onset AF
develops after TAVI.
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